Share-based Payment Arrangement, Expense in USD of NeuBase Therapeutics, Inc. from 2015 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NeuBase Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from 2015 to Q3 2023.
  • NeuBase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2023 was $-292,343, a 157% decline year-over-year.
  • NeuBase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2023 was $-239,714, a 108% decline year-over-year.
  • NeuBase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,897,689, a 21.6% decline from 2021.
  • NeuBase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $3,696,384, a 28.8% decline from 2020.
  • NeuBase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $5,194,784, a 42% decline from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

NeuBase Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2023 $-239,714 $-292,343 -$802,955 -157% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $563,241 $245,012 -$396,034 -62% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $959,275 $316,689 -$636,139 -67% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $1,595,414 $-509,072 -$1,302,276 -164% 01 Oct 2022 31 Dec 2022 10-QT 05 Jun 2023 2022 Q1
Q3 2022 $2,897,690 $510,612 -$441,897 -46% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $3,339,587 $641,046 +$15,864 +2.5% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $3,323,723 $952,828 +$10,720 +1.1% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $3,313,003 $793,204 -$383,381 -33% 01 Oct 2021 31 Dec 2021 10-QT 05 Jun 2023 2022 Q1
Q3 2021 $3,696,384 $952,509 -$187,924 -16% 01 Jul 2021 30 Sep 2021 10-K 21 Dec 2022 2022 FY
Q2 2021 $3,884,308 $625,182 -$585,533 -48% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q3
Q1 2021 $4,469,841 $942,108 -$397,302 -30% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q2
Q4 2020 $4,867,143 $1,176,585 -$327,641 -22% 01 Oct 2020 31 Dec 2020 10-Q 11 Feb 2022 2022 Q1
Q3 2020 $5,194,784 $1,140,433 -$5,451,491 -83% 01 Jul 2020 30 Sep 2020 10-K 23 Dec 2021 2021 FY
Q2 2020 $10,646,275 $1,210,715 +$391,147 +48% 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q3
Q1 2020 $10,255,128 $1,339,410 +$85,239 +6.8% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q2
Q4 2019 $10,169,889 $1,504,226 +$1,210,923 +413% 01 Oct 2019 31 Dec 2019 10-Q 11 Feb 2021 2021 Q1
Q3 2019 $8,958,966 $6,591,924 01 Jul 2019 30 Sep 2019 10-K 23 Dec 2020 2020 FY
Q2 2019 $819,568 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q3
Q1 2019 $1,254,171 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q2
Q4 2018 $293,303 01 Oct 2018 31 Dec 2018 10-Q 26 Mar 2020 2020 Q1
Q2 2016 $610,822 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2016 2016 Q3
Q1 2016 $1,407,556 01 Jan 2016 31 Mar 2016 10-Q 10 May 2016 2016 Q2

NeuBase Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $2,897,689 -$798,695 -22% 01 Oct 2021 30 Sep 2022 10-K 21 Dec 2022 2022 FY
2021 $3,696,384 -$1,498,400 -29% 01 Oct 2020 30 Sep 2021 10-K 21 Dec 2022 2022 FY
2020 $5,194,784 -$3,764,182 -42% 01 Oct 2019 30 Sep 2020 10-K 23 Dec 2021 2021 FY
2019 $8,958,966 01 Oct 2018 30 Sep 2019 10-K 23 Dec 2020 2020 FY
2015 $316,819 01 Jan 2015 31 Dec 2015 10-Q 09 Feb 2016 2016 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.